Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194

1.

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group.

N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.

PMID:
29863955
2.

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tang Y, Wilner KD, Blackhall F, Mok TS.

J Clin Oncol. 2018 May 16:JCO2017774794. doi: 10.1200/JCO.2017.77.4794. [Epub ahead of print]

PMID:
29768118
3.

Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.

Smit EF, Garon EB, Reck M, Cappuzzo F, Bidoli P, Cohen RB, Gao L, O'Brien LM, Lee P, Zimmermann A, Ferry DR, Melemed AS, Pérol M.

Cancer Chemother Pharmacol. 2018 May 2. doi: 10.1007/s00280-018-3560-5. [Epub ahead of print]

PMID:
29721850
4.

Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC).

Vecchiarelli S, Passiglia F, D'Incecco A, Gallo M, De Luca A, Rossi E, D'Incà F, Minuti G, Landi L, Bennati C, Spreafico M, D'Arcangelo M, Mazza V, Normanno N, Cappuzzo F.

Oncotarget. 2018 Apr 3;9(25):17554-17563. doi: 10.18632/oncotarget.24785. eCollection 2018 Apr 3.

5.

Lung Cancer Update 2017: from the test tube to the bed.

Bertolaccini L, Cappuzzo F, Solli P.

Ann Transl Med. 2018 Mar;6(5):86. doi: 10.21037/atm.2018.02.25. No abstract available.

6.

HER2 Deregulation in Lung Cancer: Right Time to Adopt an Orphan?

Cappuzzo F, Landi L.

Clin Cancer Res. 2018 Jun 1;24(11):2470-2472. doi: 10.1158/1078-0432.CCR-18-0198. Epub 2018 Mar 1.

PMID:
29496760
7.

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.

Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziuszko R, Ettinger D, Fennell D, Kerr K, Le Chevalier T, Leighl N, Papotti M, Paz-Ares L, Pérol M, Peters S, Pirker R, Quoix E, Reck M, Smit E, Vokes E, van Zandwijk N, Zhou C.

ESMO Open. 2017 Jan 13;1(6):e000118. doi: 10.1136/esmoopen-2016-000118. eCollection 2016.

8.

Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.

Cappuzzo F, Soo R, Hochmair M, Schuler M, Lam KC, Stehle G, Cseh A, Lorence RM, Linden S, Forman ND, Hilbe W, Jazieh AR, Tsai CM.

Future Oncol. 2018 Jan 29. doi: 10.2217/fon-2017-0666. [Epub ahead of print]

9.

Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.

Reck M, Paz-Ares L, Bidoli P, Cappuzzo F, Dakhil S, Moro-Sibilot D, Borghaei H, Johnson M, Jotte R, Pennell NA, Shepherd FA, Tsao A, Thomas M, Carter GC, Chan-Diehl F, Alexandris E, Lee P, Zimmermann A, Sashegyi A, Pérol M.

Lung Cancer. 2017 Oct;112:181-187. doi: 10.1016/j.lungcan.2017.07.038. Epub 2017 Aug 5.

10.

A few pills twice a day keep ALK-positive non-small-cell lung cancer at bay.

Landi L, Cappuzzo F.

J Thorac Dis. 2017 Aug;9(8):2311-2314. doi: 10.21037/jtd.2017.07.76. No abstract available.

11.

Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib.

Mazza V, Cappuzzo F.

Appl Clin Genet. 2017 Jul 26;10:49-56. doi: 10.2147/TACG.S103471. eCollection 2017. Review.

12.

Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Ardizzoni A, Barberis M, Cappuzzo F, Casaluce F, Danesi R, Troncone G, De Marinis F.

Transl Lung Cancer Res. 2017 Jun;6(3):373-386. doi: 10.21037/tlcr.2017.05.09. Review.

13.

Crizotinib: from discovery to accelerated development to front-line treatment.

Blackhall F, Cappuzzo F.

Ann Oncol. 2018 Apr 1;29(4):1073. doi: 10.1093/annonc/mdx121. No abstract available.

PMID:
28398575
14.

Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC.

Landi L, Cappuzzo F.

Transl Lung Cancer Res. 2016 Dec;5(6):579-587. doi: 10.21037/tlcr.2016.12.05. Review.

15.

The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer.

Gemmill RM, Nasarre P, Nair-Menon J, Cappuzzo F, Landi L, D'Incecco A, Uramoto H, Yoshida T, Haura EB, Armeson K, Drabkin HA.

Sci Signal. 2017 Jan 17;10(462). pii: eaag0528. doi: 10.1126/scisignal.aag0528.

16.

PS01.53: First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program: Topic: Medical Oncology.

Jotte RM, Socinski MA, Reck M, Papadimitrakopoulou V, West HJ, Mok T, Sandler A, Mocci S, Coleman S, Asakawa T, Cappuzzo F.

J Thorac Oncol. 2016 Nov;11(11S):S302-S303. doi: 10.1016/j.jtho.2016.09.088. Epub 2016 Oct 28. No abstract available.

17.

Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches.

Mazza V, Cappuzzo F.

J Thorac Dis. 2016 Oct;8(10):E1348-E1350. No abstract available.

18.

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Drilon A, Cappuzzo F, Ou SI, Camidge DR.

J Thorac Oncol. 2017 Jan;12(1):15-26. doi: 10.1016/j.jtho.2016.10.014. Epub 2016 Oct 26. Review.

19.

Crizotinib: from discovery to accelerated development to front-line treatment.

Blackhall F, Cappuzzo F.

Ann Oncol. 2016 Sep;27 Suppl 3:iii35-iii41. doi: 10.1093/annonc/mdw304. Review.

PMID:
27573754
20.

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.

Cappuzzo F, Morabito A, Normanno N, Bidoli P, Del Conte A, Giannetta L, Montanino A, Mazzoni F, Buosi R, Burgio MA, Cerea G, Chiari R, Cortinovis D, Finocchiaro G, Foltran L, Migliorino MR, Tiseo M, Ferrari S, De Marinis F.

Lung Cancer. 2016 Sep;99:31-7. doi: 10.1016/j.lungcan.2016.06.008. Epub 2016 Jun 14.

PMID:
27565910
21.

EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center.

Giannini R, Lupi C, Sensi E, Alì G, Proietti A, Boldrini L, Servadio A, Giordano M, Macerola E, Bruno R, Borrelli N, Chella A, Melfi F, Lucchi M, Ribechini A, Vasile E, Cappuzzo F, Mussi A, Fontanini G.

Oncol Rep. 2016 Aug;36(2):1166-72. doi: 10.3892/or.2016.4874. Epub 2016 Jun 14.

PMID:
27373829
22.

Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer.

Romanidou O, Landi L, Cappuzzo F, Califano R.

Ther Adv Med Oncol. 2016 May;8(3):176-87. doi: 10.1177/1758834016631531. Epub 2016 Feb 16. Review.

23.

cMET Exon 14 Skipping: From the Structure to the Clinic.

Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, Cappuzzo F, Hirsch FR, Rolfo C.

J Thorac Oncol. 2016 Sep;11(9):1423-32. doi: 10.1016/j.jtho.2016.05.005. Epub 2016 May 17. Review.

24.

137O: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling analyses.

Lena H, Rizvi NA, Wolf J, Cappuzzo F, Zalcman G, Baas P, Mazieres J, Farsaci B, Blackwood-Chirchir MA, Ramalingam S.

J Thorac Oncol. 2016 Apr;11(4 Suppl):S115-6. doi: 10.1016/S1556-0864(16)30247-7. Epub 2016 Apr 15. No abstract available.

25.

Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?

Califano R, Romanidou O, Mountzios G, Landi L, Cappuzzo F, Blackhall F.

Drugs. 2016 May;76(8):831-40. doi: 10.1007/s40265-016-0578-z. Review.

PMID:
27129321
26.

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.

Chatterjee M, Turner DC, Felip E, Lena H, Cappuzzo F, Horn L, Garon EB, Hui R, Arkenau HT, Gubens MA, Hellmann MD, Dong D, Li C, Mayawala K, Freshwater T, Ahamadi M, Stone J, Lubiniecki GM, Zhang J, Im E, De Alwis DP, Kondic AG, Fløtten Ø.

Ann Oncol. 2016 Jul;27(7):1291-8. doi: 10.1093/annonc/mdw174. Epub 2016 Apr 26.

27.

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS.

J Clin Oncol. 2016 Aug 20;34(24):2858-65. doi: 10.1200/JCO.2015.63.5888. Epub 2016 Mar 28.

PMID:
27022118
28.

Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.

Pérol M, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Kowalyszyn RD, Pikiel J, Lewanski CR, Thomas M, Dakhil S, Kim JH, Karaseva N, Yurasov S, Zimmermann A, Lee P, Carter GC, Reck M, Cappuzzo F, Garon EB.

Lung Cancer. 2016 Mar;93:95-103. doi: 10.1016/j.lungcan.2016.01.007. Epub 2016 Jan 19.

PMID:
26898621
29.

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.

Del Re M, Tiseo M, Bordi P, D'Incecco A, Camerini A, Petrini I, Lucchesi M, Inno A, Spada D, Vasile E, Citi V, Malpeli G, Testa E, Gori S, Falcone A, Amoroso D, Chella A, Cappuzzo F, Ardizzoni A, Scarpa A, Danesi R.

Oncotarget. 2017 Feb 21;8(8):13611-13619. doi: 10.18632/oncotarget.6957.

30.

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.

Klughammer B, Brugger W, Cappuzzo F, Ciuleanu T, Mok T, Reck M, Tan EH, Delmar P, Klingelschmitt G, Yin AY, Spleiss O, Wu L, Shames DS.

J Thorac Oncol. 2016 Apr;11(4):545-55. doi: 10.1016/j.jtho.2015.12.107. Epub 2016 Jan 8.

31.

microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.

Gasparini P, Cascione L, Landi L, Carasi S, Lovat F, Tibaldi C, Alì G, D'Incecco A, Minuti G, Chella A, Fontanini G, Fassan M, Cappuzzo F, Croce CM.

Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):14924-9. doi: 10.1073/pnas.1520329112. Epub 2015 Nov 16.

32.

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, Cappuzzo F, Cortot A, Moro-Sibilot D, Milia J, Gautschi O.

Ann Oncol. 2016 Feb;27(2):281-6. doi: 10.1093/annonc/mdv573. Epub 2015 Nov 23.

PMID:
26598547
33.

Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.

Landi L, Cappuzzo F.

Expert Rev Clin Pharmacol. 2016;9(2):203-14. doi: 10.1586/17512433.2016.1122518. Epub 2015 Dec 16. Review.

PMID:
26582431
34.

Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.

Minuti G, D'Incecco A, Cappuzzo F.

Drugs Aging. 2015 Nov;32(11):907-16. doi: 10.1007/s40266-015-0305-6. Review.

PMID:
26446154
35.

Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials.

Osarogiagbon RU, Cappuzzo F, Ciuleanu T, Leon L, Klughammer B.

Transl Lung Cancer Res. 2015 Aug;4(4):465-74. doi: 10.3978/j.issn.2218-6751.2015.07.17.

36.

Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study.

Barni S, Maiello E, Di Maio M, Ardizzoni A, Cappuzzo F, Maranzano E, Novello S, Bennati C, Ori A, Rizzoli S, Crinò L; RIGHT-3 study group.

Lung Cancer. 2015 Nov;90(2):234-42. doi: 10.1016/j.lungcan.2015.08.005. Epub 2015 Aug 19.

37.

Experience with erlotinib in the treatment of non-small cell lung cancer.

Landi L, Cappuzzo F.

Ther Adv Respir Dis. 2015 Aug;9(4):146-63. doi: 10.1177/1753465815588053. Epub 2015 Jun 10. Review.

PMID:
26063687
38.

Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study.

D'Arcangelo M, Todaro M, Salvini J, Benfante A, Colorito ML, D'Incecco A, Landi L, Apuzzo T, Rossi E, Sani S, Stassi G, Cappuzzo F.

PLoS One. 2015 May 8;10(5):e0125037. doi: 10.1371/journal.pone.0125037. eCollection 2015.

39.

Onartuzumab in lung cancer: the fall of Icarus?

Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F.

Expert Rev Anticancer Ther. 2015 May;15(5):487-9. doi: 10.1586/14737140.2015.1031219. Epub 2015 Mar 30.

PMID:
25818471
40.

cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance.

Van Der Steen N, Pauwels P, Gil-Bazo I, Castañon E, Raez L, Cappuzzo F, Rolfo C.

Cancers (Basel). 2015 Mar 25;7(2):556-73. doi: 10.3390/cancers7020556. Review.

41.

Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer.

Landi L, Cappuzzo F.

Ann Transl Med. 2015 Mar;3(3):32. doi: 10.3978/j.issn.2305-5839.2015.02.12. No abstract available.

42.

Targeting MET in NSCLC: looking for a needle in a haystack.

Landi L, Cappuzzo F.

Transl Lung Cancer Res. 2014 Dec;3(6):389-91. doi: 10.3978/j.issn.2218-6751.2014.11.05. No abstract available.

43.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS.

Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. Epub 2015 Feb 20.

44.

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T, Dingemans AM, Léna H, Monnet I, Rothschild SI, Cappuzzo F, Besse B, Thiberville L, Rouvière D, Dziadziuszko R, Smit EF, Wolf J, Spirig C, Pecuchet N, Leenders F, Heuckmann JM, Diebold J, Milia JD, Thomas RK, Gautschi O.

J Clin Oncol. 2015 Mar 20;33(9):992-9. doi: 10.1200/JCO.2014.58.3302. Epub 2015 Feb 9.

PMID:
25667280
45.

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.

Cappuzzo F, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpré P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J.

Lung Cancer. 2015 Feb;87(2):89-95. doi: 10.1016/j.lungcan.2014.12.010. Epub 2014 Dec 18. Review.

46.

Nit-picking around second line in EGFRwt NSCLC: just an academic effort.

Landi L, Cappuzzo F.

Ann Oncol. 2015 Mar;26(3):448-50. doi: 10.1093/annonc/mdu575. Epub 2014 Dec 19. No abstract available.

PMID:
25527415
47.

Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.

Cappuzzo F, Finocchiaro G, Grossi F, Bidoli P, Favaretto A, Marchetti A, Valente ML, Cseh A, Clementi L, Massey D, Santoro A.

J Thorac Oncol. 2015 Apr;10(4):665-72. doi: 10.1097/JTO.0000000000000442.

48.

The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target?

Passiglia F, Van Der Steen N, Raez L, Pauwels P, Gil-Bazo I, Santos E, Santini D, Tesoriere G, Russo A, Bronte G, Zwaenepoel K, Cappuzzo F, Rolfo C.

Curr Drug Targets. 2014;15(14):1284-92. Review.

PMID:
25511614
49.

Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer.

Stasi I, Cappuzzo F.

Transl Respir Med. 2014 Jan 6;2:2. doi: 10.1186/2213-0802-2-2. eCollection 2014.

50.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators.

N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440. Erratum in: N Engl J Med. 2015 Oct 15;373(16):1582.

Supplemental Content

Loading ...
Support Center